DR. PANKAJ NAINWAL
Abstract
Simvastatin is a cholesterol-lowering medication that may be used to treat hypercholesterolemia, coronary heart disease, and dyslipidemia. Simvastatin (SV), on the other hand, has been proven to have poor oral absorption in the GI tract. Developing proliposomal formulations was undertaken with the sole intent of increasing SV's oral bioavailability. The proliposomes were made using a film deposition on carrier technique. Morphology, entrapment efficiency, drug-polymer compatibility, and in vitro and in vivo tests were all evaluated for the proliposomes. There was no evidence of a drug-polymer interaction in the FTIR or DSC analyses. The maximum medication release time observed with the optimized formulation (PL6) was 12 hours (99.78 0.067%). Pure SV had a maximum plasma concentration of 10.4 2.921 g/mL and an elimination half-life of 67.124 0.23 hours, whereas SV proliposomes (SVP) had an AUC0- of 179.75 1.541 hours. The adjusted SVP significantly improves SV rate and uptake.